Vanda Presents Phase III Iloperidone Efficacy Data

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced that data from four Phase III efficacy and safety trials demonstrate that iloperidone, an investigational atypical antipsychotic, is associated with significantly greater improvements in the symptoms of schizophrenia versus placebo and has a favorable safety and tolerability profile. These results were included as part of the recently filed New Drug Application (NDA) for iloperidone and were presented for the first time this week at a major psychiatric congress. Posters containing the data presented will be posted on Vanda's Web site, http://www.vandapharma.com/, on Thursday, December 13, 2007. The U.S. Food and Drug Administration (FDA)...

Want to see the full article?

• Purchase this article for only $3.00